Previous 10 | Next 10 |
MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that the first patien...
Gainers: VNRX +5.5% . AIR +4.1% . EGO +3.4% . VAC +2.9%. PHAS +1.5% . More news on: VolitionRx Limited, AAR Corp., Eldorado Gold Corporation, Stocks on the move, Read more ...
Gainers: Emmaus Life Sciences ( OTC:EMMA ) +64% . PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +23% . SYNNEX Corporation (NYSE: SNX ) +20% . Contango Oil & Gas Company (NYSEMKT: MCF ) +17% . R.R. Donnelley & Sons Company (NYSE: RRD ) +16% . Comtech Telecommunications (NASDAQ...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +21% on end of PB2452 trial . More news on: PhaseBio Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Philip Morris International Inc., Stocks on the move, Read more ...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) is up 14% postmarket after reporting the completion of its Phase 2a trial of PB2452 . More news on: PhaseBio Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
MALVERN, Pa. and SAN DIEGO, Sept. 24, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary orphan diseases, today announced the completio...
Oramed Pharmaceuticals (NASDAQ: ORMP ) initiated with Buy rating and $7 (136% upside) at Ladenburg Thalmann. Shares up 3% premarket. More news on: Oramed Pharmaceuticals Inc., PhaseBio Pharmaceuticals, Inc., Bicycle Therapeutics plc, Healthcare stocks news, Stocks on the move, ...
Gainers : Pier 1 Imports (NYSE: PIR ) +28% . Endo International (NASDAQ: ENDP ) +24% . Autolus Therapeutics (NASDAQ: AUTL ) +25% . Microbot Medical (NASDAQ: MBOT ) +24% . Hovnanian Enterprises (NYSE: HOV ) +20% . Lannett Company (NYSE: LCI ) +20% . DocuSign (NASDAQ: DOCU ) +19% . Su...
MALVERN, Pa. and SAN DIEGO, Sept. 03, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that data from an evaluation ...
MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that pharmacodynamic data from t...
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...